Interview with Mark Fladrich, Managing Director, Australia & New Zealand,…
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
Address: 5 Alma Road, North Ryde NSW 2113,Australia
Tel: +61 2 9978 3500
Web: http://www.astrazeneca.com.au/home/
AstraZeneca Australia is engaged in the research, development, manufacture and supply of medicines that aim to make a real difference to the lives of Australians.
AstraZeneca is one of Australia’s largest private sector investors in medical research and development (R&D) and has, invested more than $250 million in Australia in the last decade.
It is the largest national manufacturer of pharmaceuticals in Australia, providing $1.2 billion of medicines to the local market and $200 million in exports.
AstraZeneca currently involved in more than 50 clinical trials at over 200 sites across Australia, investigating potential new treatments in the areas of oncology, cardiovascular, diabetes, infection, gastrointestinal, neuroscience, respiratory, and inflammation.
The company employs more than 900 people in Australia and is committed to being recognised as an ‘Employer of Choice’.
AstraZeneca couples a global reach with local knowledge that stems from its long heritage in Australia that dates back to 1957.
AstraZeneca focuses on the following health care areas: cardiovascular, diabetes, gastrointestinal, neuroscience, oncology, respiratory, anaesthesia and pain management.
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although that doesn’t preclude the company…
Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines…
To begin, would you please give a brief introduction to the PBAC? The PBAC is a statutory committee of government first developed in Australia in the 1940s, which advises the…
The Ministry for Innovation, Industry, Science and Research was created in December 2007 with the election of the Labor government. To begin, would you please give a brief introduction to…
Would you please introduce Pierre Fabre to our readers? Pierre Fabre Medicament Australia Pty Limited was established in Australia in late 2001, and is a fully owned subsidiary of the…
The Australian pharmaceutical sector has seen recent innovations through PBS reform and various working groups shaping the future of the industry. Can you comment on how Datapharm is reacting to…
What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of…
See our Cookie Privacy Policy Here
